ArticleAdvances in radiation oncology

A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis.

Laura Callan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.